Global Cell-free Protein Expression Market Size will Reach $276.35 Million in 2023

Global Cell-free Protein Expression Market Overview

Global cell-free protein expression market size will reach $276.35 million in 2023 with a CAGR of 6.96% from 2023 to 2028.

The significant factors for the growth of the cell-free protein expression market include the increasing R&D in proteomics and genomics, the high prevalence of cancer and infectious diseases, and shorter expression time and structural modification. Cell-free protein expression employs cell lysates to produce the desired recombinant proteins, averting to workflow hurdles of maintaining cell culture or living cells. Cell lysates are produced by the breakdown and use of cellular components of eukaryotic or bacterial cells. Several cell-free protein expression systems are currently commercially available, based on E. coli, rabbit reticulocytes, wheat germs, human cell lines, and insect cells.

North America Dominates the Market

North America holds a major share in the cell-free protein expression market, and it is expected to show a similar trend over the forecast period without significant fluctuations. The primary factors behind the large market size include the increasing prevalence of chronic diseases, such as cancer, the aging population, the growing demand for targeted and personalized medicine, the presence of major R&D facilities, and favorable government initiatives in the United States. There is a growing trend of cell-based research in the US academia and biotechnology industries. In recent years, several government initiatives have been supplementing the growth of the cell-free protein expression market in the United States.In North America, the US holds the largest market share due to factors such as the increasing burden of cancer cases in the country, which is anticipated to stimulate the demand for cell-free protein expression market.

Cell-free Protein Expression Market News

In January 2022, Merck KGaA acquired Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately USD 780 million.

In January 2022, Thermo Fisher Scientific Inc. acquired PeproTech for approximately USD 1.85 billion. Through this acquisition, PeproTech's recombinant proteins portfolio will complement Thermo Fisher's cell culture media products and further enable it to provide its customers significant benefits through an integrated offering.

Thermo Fisher Scientific is one of the major players operating in the cell-free protein expression market, holding a share of 21.56% in 2022. Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals. The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.

Company Name	Thermo Fisher Scientific
Website	www.thermofisher.com
Established Time	1960
Distribution Region	Worldwide
Service Introduction	Thermo Fisher Scientific has several optimized cell-free expression systems for the rapid synthesis of recombinant proteins utilizing rabbit reticulocyte, or HeLa-based lysate systems. These mammalian systems can produce full-length and functionally active proteins, with the HeLa systems typically expressing higher protein yields than the rabbit reticulocyte system.